Pediatr Emerg Med J.  2024 Apr;11(2):82-87. 10.22470/pemj.2024.00941.

Is the combination of domperidone and metoclopramide increasing the risk of developing serotonin syndrome?: a case report

• Aldosari AN
• Alzahrani A
• Alghamdi M
• Alzahrani A
• Alghamdi A

• KMID: 2554080
• DOI: http://doi.org/10.22470/pemj.2024.00941

Abstract

Metoclopramide and domperidone are dopamine antagonists that can cause an acute dystonic reaction. Metoclopramide is a rare but major contributor to serotonin syndrome, particularly when used with other serotonergic agents. Serotonin syndrome is a rare, potentially life-threatening adverse reaction characterized by a triad of altered mental status, autonomic dysfunction, and neuromuscular hyperactivity that typically results from exposure to serotonergic agents. Herein, we report a previously healthy 9-year-old girl who was brought to the emergency department with an alteration in the level of conscious and involuntary repetitive movements after approximately 24 hours of receiving a therapeutic dose of metoclopramide and domperidone. Physical examination showed tachycardia, hyperthermia, and a Glasgow Coma Scale score of 11, as well as mydriasis and hyperreflexia. In addition to resolving the symptoms after administering midazolam and diphenhydramine, the diagnosis of serotonin syndrome was made based on the classical symptoms and signs, which met the Hunter criteria. This case indicates the need for clinical awareness of the life-threatening syndrome and caution with medications having potential interactions with metoclopramide.

Keyword

Domperidone; Dystonia; Metoclopramide; Pediatrics; Serotonin Syndrome

Reference

References

1. Simon LV, Keenaghan M. Serotonin syndrome [updated 2023 Jul 17]. In: StatPearls [Internet]. StatPearls Publishing; 2023. Available from: Available from: https://www.ncbi.nlm.nih.gov/books/NBK482377/.

2. Isola S, Hussain A, Dua A, et al. In: StatPearls [Internet]. StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519517/.

3. Puoti MG, Assa A, Benninga M, Broekaert IJ, Carpi FJ, Deganello Saccomani M, et al. Drugs in focus: domperidone. J Pediatr Gastroenterol Nutr. 2023; 77:e13–22.

4. D’Souza RS, Hooten WM. Extrapyramidal symptoms [updated 2023 Jul 31]. In: StatPearls [Internet].: StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534115/.

5. Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions. Int J Tryptophan Res. 2019; 12:1178646919873925.

6. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007; 102:2036–45.

7. Koban Y, Ekinci M, Cagatay HH, Yazar Z. Oculogyric crisis in a patient taking metoclopramide. Clin Ophthalmol. 2014; 8:567–9.

8. Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitorsmetoclopramide interaction. Ann Pharmacother. 2002; 36:67–71.

9. Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab. 2010; 5:653–62.

10. Tormoehlen LM, Rusyniak DE. Neuroleptic malignant syndrome and serotonin syndrome. Handb Clin Neurol. 2018; 157:663–75.

11. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005; 352:1112–20.

12. Chiew AL, Buckley NA. The serotonin toxidrome: shortfalls of current diagnostic criteria for related syndromes. Clin Toxicol (Phila). 2022; 60:143–58.

13. Broderick ED, Metheny H, Crosby B. Anticholinergic Toxicity [updated 2023 Apr 30]. In: StatPearls [Internet]. StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534798/.

14. Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin. 1997; 13:763–83.

15. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000; 79:201–209.

16. Ali SZ, Taguchi A, Rosenberg H. Malignant hyperthermia. Best Pract Res Clin Anaesthesiol. 2003; 17:519–33.

17. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999; 13:100–9.

18. Sicari V, Zabbo CP. Diphenhydramine [updated 2023 Jul 10]. In: StatPearls [Internet]. StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526010/.

19. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998; 16:615–9.